EGFR and lung adenocarcinoma: Our group has previously reported on the mechanisms by which tumors acquire resistance against third-generation EGFR-TKIs (osimertinib and rociletinib) using afatinib-resistant lung adenocarcinoma PC-9 cells harboring an acquired T790M mutation in EGFR [9].